Efeitos da radioiodoterapia nas glândulas salivares
DOI:
https://doi.org/10.26843/ro_unicid.v23i3.380Palavras-chave:
Neoplasias da glândula tireoide, Radioisótopos do iodo, Glândulas salivares .Resumo
O carcinoma diferenciado de glândula tireoide (CDT) é a neoplasia maligna mais comum do sistema endócrino. O prognóstico quase sempre é favorável, sendo melhor nos casos de carcinomas diferenciados. O tratamento considerado mais adequado para esses casos, a tiroidectomia total seguida de ablação actínica com iodo radioativo (131I), oferece ao paciente uma sobrevida longa. O radioiodo usado para tratar os pacientes com câncer de tireoide é absorvido não só pelos tecidos tireoideanos, mas também pelas glândulas salivares. Consequentemente, a radiação β do 131 I exerce efeitos citotóxicos nas glândulas salivares por serem estas altamente radiosensíveis. O presente trabalho consiste em uma revisão de literatura objetivando listar os efeitos da radioiodoterapia nas glândulas salivares, considerando o bom prognóstico da doença e a necessidade da qualidade de vida dos pacientes acometidos com o câncer de tireoide. A literatura aponta que, clinicamente, xerostomia, dificuldade de deglutição e perda do paladar são os sintomas mais citados, porém, a frequência das complicações após a terapia com 131 I são incertas, havendo a necessidade de maiores esclarecimentos sobre o assunto, na medida em que é necessária a criação e implementação de protocolos eficientes na diminuição e erradicação desses sintomas, garantindo, assim, uma boa qualidade de vida ao paciente com CDT que foi tratado.Downloads
Referências
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Câncer da tireoide: condutas do INCA Rev bras cancerol 2002 abr.-jun.;48(2):181-5
Ward LS, Assumpção LVM. Câncer diferenciado da tiroide: fatores prognósticos e tratamento. Arq Bras Endocrinol Metab 2004 Feb.;48(1):126-36.
Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord 2000 Jan;1(1-2):19-25.
Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/ iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003 Feb;24(1):48-77.
]Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001 May;42(5):738-43.
Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003 Mar;13(3):265-71.
Mandel SJ, Mandel L. False-positive xerostomia following radioactive iodine treatment: case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 Feb;103(2):e43-7.
Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 2010 Dec;37(12):2298-306.
Aframian DJ, Helcer M, Livni D, Markitziu A. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis 2006 May;12(3):297-300.
Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 1998 Jul;39(7):1237-42.
.Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007 Oct 1;110(7):1451-6.
Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 2010 Jun 30;322(1-2):8-28
Pinto A, Glick M. Management of patients with thyroid disease: oral health considerations. J Am Dent Assoc 2002 Jul;133(7):849-58.
Maia AL, Ward LS, Carvalho GA, Graf H, Maciel RMB, Maciel LMZ, et al. Nódulos de tireoide e câncer diferenciado de tireoide: consenso brasileiro. Arq Bras Endocrinol Metab 2007 July;51(5):867-93.
Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002 Mar 1;52(3):784-95.
Van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, et al. Salivary gland protection with sialagogues: a case study. Thyroid 2009 Sep;19(9):1005-8.
Clarke SE. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective. Clin Oncol (R Coll Radiol) 2010 Aug;22(6):430-7.
Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998 Sep;39(9):1551-4.
Brandão CDG, Antonucci J, Correa ND, Corbo R, Vaisman M. Efeitos da radioiodoterapia nas gerações futuras de mulheres com carcinoma diferenciado de tireoide. Radiol Bras 2004 37(1):51-5.
Liu B, Kuang A, Huang R, Zhao Z, Zeng Y, Wang J, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med 2010 Apr;51(4):618-23.
Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002 Nov;27(11):767-71.
Nahlieli O, Nazarian Y. Sialadenitis following radioiodine therapy - a new diagnostic and treatment modality. Oral Dis 2006 Sep;12(5):476-9.
.Rodrigues M, Havlik E, Peskar B, Sinzinger H. Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy? Eur J Nucl Med 1998 Mar;25(3):265-9.
Newkirk KA, Ringel MD, Wartofsky L, Burman KD. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J 2000 Jun;79(6):460-8.
Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007 Feb;19(1):83-6.
.Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010 Aug;37(9):1778-85.
Laupa MS, Toth BB, Keene HJ, Sellin RV. Effect of radioactive iodine therapy on salivary flow rates and oral Streptococcus mutans prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol 1993 Mar;75(3):312-7.
Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996 Jun 1;35(3):535-40.
Epstein JB, Barasch A. Taste disorders in cancer patients: pathogenesis, and approach to assessment and management. Oral Oncol 2010 Feb;46(2):77-81.
Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009 Oct;50(10):1605-10.
Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, Vasko V, Chia S, Deng T, et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid 2010 Jun;20(6):647-51.
Mandel SJ, Mandel L. Persistent sialadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg 1999 Jun;57(6):738-41.
Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009 Dec;19(12):1381-91.
Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005 Feb;46(2):261-6.
Kutta H, Kampen U, Sagowski C, Brenner W, Bohuslavizki KH, Paulsen F. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlenther Onkol 2005 Apr;181(4):237-45.
